Overview
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Eligibility
Inclusion Criteria:
- Chronic AD that has been present for ≥6 months
- Validated-Investigator's Global Assessment score of ≥3
- EASI of ≥16
- BSA of AD involvement of ≥10%
Exclusion Criteria:
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
- Use of certain medications
- Presence of skin comorbidities or other condition(s) that may interfere with study assessments
- Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry